Coronavac directed public policy decisions and is the protagonist of clinical trials in Brazil, says master in health sciences
Publicado em:
01/01/1970
A science-based vaccine that was important to start discussions and decisions when Covid-19 arrived in the country. This is how Ana Marisa Chudzinski-Tavassi, director of innovation at Instituto Butantan and at the Centre of Excellence in New Target Discovery (CENTD), defines CoronaVac. The vaccine was the starting point for immunization against the new coronavirus in Brazil, in early 2020.
This is one of the themes to be discussed during the CoronaVac Symposium, an international event to be held next Tuesday (7), Wednesday (8) and Thursday (9) by Instituto Butantan and Sinovac. The meeting will bring together Brazilian researchers from different fields and specialists from the United States, Turkey, Chile, China and Spain.
The director recalls that CoronaVac is considered a protagonist, since its phase 3 clinical trials were carried out in centers across the country. The December event will bring information about all the science that was involved in developing the vaccine. “Coronavac required a lot of investigation and research work to achieve its objectives”, explains Ana Marisa.
Nós usamos cookies e outras tecnologias semelhantes em nossos sites para melhorar o desenvolvimento de conteúdo interessante para nossos visitantes. Ao utilizar nossos sites, você concorda com tal monitoramento.
